# Gallium-68 DOTATOC for Management of Neuroendocrine Tumors

> **NCT02375464** · — · NO_LONGER_AVAILABLE · sponsor: **Northwell Health**

## Conditions studied

- Neuroendocrine Tumors

## Interventions

- **DRUG:** Gallium-68 DOTATOC

## Key facts

- **NCT ID:** NCT02375464
- **Lead sponsor:** Northwell Health
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** NO_LONGER_AVAILABLE
- **Start date:** 2015-04
- **Primary completion:** 2018-12
- **Final completion:** 2019-12
- **Target enrollment:** — (—)
- **Last updated:** 2016-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02375464

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02375464, "Gallium-68 DOTATOC for Management of Neuroendocrine Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02375464. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*